Profile
Paul trained at the University of Cambridge in genetic and molecular epidemiology of cardiometabolic disease, and has been a full professor at Lund University and Harvard School of Public Health since 2010. Since 2017, Paul has also been a visiting professor at the University of Oxford. Past roles include Director of the Department of Translational Medicine at the Novo Nordisk Foundation in Denmark (2021-2024), Deputy-director of Lund University Diabetes Center in Sweden (2016-2021) and Vice-President Elect of the Nordic Society of Human Genetics and Precision Medicine (2019-2021).
From 2018-2024, Paul co-chaired the ADA/EASD Precision Medicine in Diabetes Initiative, and he has co-chaired the NIDDK Heterogeneity of Diabetes Working Group of Council since 2022. In these roles, Paul chaired the 1st and 2nd international consensus reports on precision diabetes medicine (Chung et al, Diabetes Care, 2020; Tobias et al, Nature Medicine, 2023) and the guidelines on precision medicine research of clinical relevance (Lim et al, Nature Medicine, 2024), and co-chairs the NIH Global Heterogeneity in Diabetes Initiative (Cefalu et al. Nature Medicine, 2024).
Paul’s research focuses on using multimodal data and machine learning approaches to improve prediction, prevention and treatment of cardiometabolic diseases. He has published >500 peer-reviewed papers (cited >80,000 times) and given >300 invited lectures.
Paul has received several awards including the EASD Rising Star Award, the Swedish Research Council Distinguished Young Researcher Award, Harry Keen Memorial Award for Diabetes Epidemiology, Novo Nordisk 'Leif Groop' Prize for Excellence in Diabetes Research, and an ERC Consolidator award.